2024 U.S. Revenue Highlights
-
Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty, brought in $5.35 billion in U.S. sales for 2024 Reuters.
-
Moderna’s COVID-19 vaccine, Spikevax, generated $1.8 billion in U.S. revenue in 2024 Reuters.
Combined, that’s approximately $7.15 billion in U.S. mRNA vaccine revenue for 2024.
Breakdown:
| Vaccine | Company | U.S. Revenue (2024) |
|---|---|---|
| Comirnaty | Pfizer/BioNTech | $5.35 B |
| Spikevax | Moderna | $1.8 B |
| Total | — | $7.15 B |
